Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

polio

- PMLiVE

MHRA approves second COVID-19 antibody treatment

Preclinical data for GSK and Vir’s Xevudy suggests it retains activity against Omicron and all other variants of concern

regeneron headquarters

Regeneron signs $900m cancer and infectious disease deal with Nykode

The deal with Norwegian clinical-stage vaccine specialist Nykode (previously Vaccibody) includes an upfront payment of $30m and an equity investment of $20m plus additional payments

- PMLiVE

UK’s MHRA approves first oral antiviral against COVID-19

Merck's Lagevrio has been approved for people with mild to moderate COVID-19 and at least one risk factor for developing severe illness

- PMLiVE

Future of MHRA uncertain amid Brexit-fuelled shake up

Trade unions and regulatory experts warn that budget and staff cuts may lead to drug approval delays or the UK regulator simply rubber-stamping EMA decisions

regeneron headquarters

UK approves Regeneron’s COVID-19 antibody cocktail

Ronapreve is the first monoclonal antibody therapy against COVID-19 approved in Europe

- PMLiVE

UK announces new ten-year Life Sciences Vision to support life sciences sector

UK government has launched a £200m life sciences investment programme to support innovative life sciences companies

- PMLiVE

MHRA outlines two-year delivery plan with ‘patient first’ focus

New delivery plan also outlines strategy for UK regulatory body following Brexit

- PMLiVE

MHRA grants bluebird bio’s LentiGlobin gene therapy an ‘innovation passport’

The Innovative Licensing and Access Pathway scheme aims to help speed approval of innovative treatments

- PMLiVE

Global consortium of medicines regulators reveals new strategic plan

Access Consortium includes regulators from Australia, Canada, Singapore, Switzerland and the UK

- PMLiVE

J&J’s single-dose COVID-19 vaccine secures approval from the UK’s MHRA

Vaccine was found to be 67% effective in preventing COVID-19 infection in a phase 3 study

- PMLiVE

Pfizer asks UK’s MHRA to approve its COVID-19 vaccine in adolescents

The vaccine has been authorised in the US for 12- to 15-year-olds

dengue fever mosquito

Oxford University’s malaria vaccine is 77% effective

First vaccine to meet WHO-specified efficacy goal of 75%, says research team

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links